Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

GSK2008607

Copy Product Info
😃Good
Catalog No. T27454Cas No. 1244644-50-5

GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.

GSK2008607

GSK2008607

Copy Product Info
😃Good
Purity: 99.99%
Catalog No. T27454Cas No. 1244644-50-5
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$350In StockIn Stock
5 mg$828In StockIn Stock
10 mg$1,130In StockIn Stock
25 mg$1,590In StockIn Stock
50 mg$1,980In StockIn Stock
100 mg$2,500In StockIn Stock
500 mg$4,900-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.99%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

GSK2008607 AI Summary
GSK2008607 demonstrates significant bioactivity across multiple assays and species. It exhibits intrinsic clearance in rat liver microsomes at a rate of 10.0 mL.min-1.g-1. The compound shows potent antiproliferative activity against human SK-MEL-28 cells expressing the B-Raf V600E mutant, with an EC50 of 8.0 nM after 3 days. Additionally, it effectively inhibits ERK phosphorylation in these cells with an EC50 of 11.0 nM after 1 hour and directly inhibits the B-Raf V600E mutant with an IC50 of 0.5 nM. In pharmacokinetic studies, GSK2008607 has high oral bioavailability in rats (85.0%), but much lower bioavailability in monkeys (5.0%) and dogs (10.0%). The dose-normalized AUC values are significantly higher in rats (1748.0 ng.hr/ml/mg/kg) compared to monkeys (23.0 ng.hr/ml/mg/kg) and dogs (42.0 ng.hr/ml/mg/kg). Blood clearance is highest in monkeys (39.0 mL.min-1.kg-1) followed by dogs (38.0 mL.min-1.kg-1) and rats (9.0 mL.min-1.kg-1). The compound shows marginal to moderate bioactivity in reducing the motility of O. lienalis microfilariae, with a 93.4% reduction, and has been tested for cytotoxicity against Rhesus Monkey LLCMK2 cells. In terms of inhibition of NEK proteins, GSK2008607 exhibits very high inhibition of NEK3 (99.0%) and NEK10 (100.0%), moderate inhibition of NEK4 (49.0%) and NEK5 (24.0%), and lower inhibition of NEK7 (7.1%), NEK9 (6.4%), and NEK11 (1.4%). Minimal inhibition is observed on NEK2 and NEK6 (0.9% each). These results indicate GSK2008607's potential as a targeted inhibitor, particularly against NEK3 and NEK10, as well as its potent anticancer activity through B-Raf V600E mutant inhibition..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
Targets&IC50
B-Raf:< 0.1 µM, B-Raf:0.008 µM(EC50)
Chemical Properties
Molecular Weight667.72
FormulaC31H28F3N7O3S2
Cas No.1244644-50-5
SmilesC(C)(C)C=1SC(=C(N1)C2=C(F)C(NS(=O)(=O)C3=C(F)C=CC=C3F)=CC=C2)C4=NC(NC=5C=CC(=NC5)N6CCOCC6)=NC=C4
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 50 mg/mL (74.88 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.4976 mL7.4882 mL14.9763 mL74.8817 mL
5 mM0.2995 mL1.4976 mL2.9953 mL14.9763 mL
10 mM0.1498 mL0.7488 mL1.4976 mL7.4882 mL
20 mM0.0749 mL0.3744 mL0.7488 mL3.7441 mL
50 mM0.0300 mL0.1498 mL0.2995 mL1.4976 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy GSK2008607 | purchase GSK2008607 | GSK2008607 cost | order GSK2008607 | GSK2008607 chemical structure | GSK2008607 formula | GSK2008607 molecular weight